Ubonelelo lweFactory 4-Bromo-2-Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7

Ukuzalisekisa ulwaneliseko olulindelekileyo kubathengi, ngoku sinabasebenzi bethu abomeleleyo ukubonelela ngoncedo lwethu ngokubanzi olubandakanya ukukhuthaza, intengiso enkulu, ukucwangcisa, ukudala, ukulawula umgangatho ophezulu, ukupakisha, ukugcinwa kunye nokuhanjiswa kweFactory Supply 4-Bromo-2 -Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7, Sinyanisekile kwaye sivulekile.Sijonge phambili kutyelelo lwakho kunye nokuseka ubudlelwane obuthembekileyo kunye nexesha elide lokuma.
Ukuzalisekisa ulwaneliseko olulindelekileyo kubathengi, ngoku sinabasebenzi bethu abomeleleyo ukuze babonelele ngoncedo lwethu ngokubanzi olubandakanya ukuthengisa, ukuthengisa, ukucwangcisa, ukudala, ukulawula umgangatho ophezulu, ukupakisha, ukugcinwa kunye nokuhanjiswa kwezinto.China CAS 112704-79-7 kunye 112704-79-7, Impahla yethu iphumelele igama elihle kwilizwe ngalinye elinxulumeneyo.Ngenxa yokusekwa kwefemu yethu.sinyanzelise inkqubo yethu yokuvelisa izinto ezintsha kunye neyona ndlela yakutshanje yokulawula, sitsala ubuninzi beetalente kweli shishini.Sithatha isisombululo esisemgangathweni njengowona mlinganiswa ubalulekileyo wethu.

I-1-Bromo-2-methoxy-3-nitro-benzene isetyenziswa njengendawo ephakathi ye-Eltrombopag.
I-Eltrombopag, ephuhliswe yi-GlaxoSmithKline (GSK) e-UK kwaye kamva iphuhliswe ngokudibeneyo kunye ne-Novartis eSwitzerland, yeyokuqala kwaye ivunyiwe kuphela i-molecule encinci ye-non peptide TPO receptor agonist emhlabeni.I-Eltrombopag yavunywa yi-US FDA kwi-2008 yonyango lwe-idiopathic thrombocytopenic purpura (ITP), kunye ne-2014 yonyango lwe-anemia ye-aplastic enzima (AA).Ikwalichiza lokuqala elavunywa yi-US FDA kunyango lwe-AA kwiminyaka engama-30 yakutsha nje.
NgoDisemba 2012, i-US FDA ivume i-Eltrombopag yonyango lwe-thrombocytopenia kwizigulane ezine-hepatitis C engapheliyo (CHC), ukwenzela ukuba izigulane ze-hepatitis C ezine-prognosis embi ngenxa yokubala kweplatelet ephantsi inokuqala kwaye igcine unyango oluqhelekileyo lwe-interferon kwizifo zesibindi.NgoFebruwari3, 2014, i-GlaxoSmithKline yabhengeza ukuba i-FDA inike isiqinisekiso sonyango lwe-Eltrombopag kunyango lwe-hemopenia kwizigulane ezine-chemicalbook aplastic anemia (SAA) ezinzima ezingazange ziphendule ngokupheleleyo kwi-immunotherapy.Ngo-Agasti 24, i-2015, i-US FDA ivume i-Eltrombopag yonyango lwe-thrombocytopenia kubantu abadala kunye nabantwana abaneminyaka eyi-1 kunye nangaphezulu kunye ne-immune immune thrombocytopenia (ITP) abangenayo impendulo eyaneleyo kwi-corticosteroids, i-immunoglobulins okanye i-splenectomy.NgoJanuwari4, 2018, i-Eltrombopag yavunywa ukuba ibhalwe e-China kunyango lwe-immune immune thrombocytopenia (ITP).

Ukuzalisekisa ulwaneliseko olulindelekileyo kubathengi, ngoku sinabasebenzi bethu abomeleleyo ukubonelela ngoncedo lwethu ngokubanzi olubandakanya ukukhuthaza, intengiso enkulu, ukucwangcisa, ukudala, ukulawula umgangatho ophezulu, ukupakisha, ukugcinwa kunye nokuhanjiswa kweFactory Supply 4-Bromo-2 -Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7, Sinyanisekile kwaye sivulekile.Sijonge phambili kutyelelo lwakho kunye nokuseka ubudlelwane obuthembekileyo kunye nexesha elide lokuma.
Ubonelelo lwefektriChina CAS 112704-79-7 kunye 112704-79-7, Impahla yethu iphumelele igama elihle kwilizwe ngalinye elinxulumeneyo.Ngenxa yokusekwa kwefemu yethu.sinyanzelise inkqubo yethu yokuvelisa izinto ezintsha kunye neyona ndlela yakutshanje yokulawula, sitsala ubuninzi beetalente kweli shishini.Sithatha isisombululo esisemgangathweni njengowona mlinganiswa ubalulekileyo wethu.